Novonesis Achieves 9% Organic Sales Growth in H1; Full-Year Outlook Adjusted to 6-8% Range
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 21 2025
0mins
Should l Buy ?
Source: Yahoo Finance
Sales Growth and Outlook: Novonesis reported a 9% organic sales growth in H1 2025, with the full-year outlook for organic sales growth narrowed to 6-8%.
Market Performance: Strong performance was noted in both emerging markets (12% growth) and developed markets (8%), with Food & Health and Planetary Health segments also showing significant growth.
Financial Highlights: Adjusted EBITDA margin increased to 37.4%, adjusted net profit rose by 23%, and cost synergies reached a 100% run rate.
Future Strategy: The company announced its long-term financial targets towards 2030, which will be discussed in an upcoming conference call.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
